UiPath Inc. (NYSE:PATH) CFO Sells $791,600.00 in Stock

UiPath Inc. (NYSE:PATH) CFO Ashim Gupta sold 40,000 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $19.79, for a total transaction of $791,600.00. Following the completion of the sale, the chief financial officer now directly owns 946,848 shares in the company, valued at approximately $18,738,121.92. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ashim Gupta also recently made the following trade(s):

• On Thursday, April 4th, Ashim Gupta sold 40,000 shares of UiPath stock. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00.
• On Friday, March 15th, Ashim Gupta sold 16,000 shares of UiPath stock. The stock was sold at an average price of $22.84, for a total value of $365,440.00.

UiPath Stock Down 0.6 %

Shares of NYSE:PATH traded down $0.13 during midday trading on Wednesday, reaching $19.89. The company had a trading volume of 4,732,252 shares, compared to its average volume of 8,341,699. The business’s 50 day moving average price is $21.60 and its 200 day moving average price is $21.78. UiPath Inc. has a 1-year low of $13.30 and a 1-year high of $27.87. The stock has a market cap of $11.32 billion, a PE ratio of -117.06 and a beta of 1.01.

UiPath (NYSE:PATH) last issued its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.10. The business had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. On average, research analysts expect that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On UiPath

A number of institutional investors and hedge funds have recently modified their holdings of the company. Royal London Asset Management Ltd. raised its position in shares of UiPath by 5.9% in the third quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock valued at $2,388,000 after purchasing an additional 7,742 shares during the period. Vestmark Advisory Solutions Inc. bought a new stake in UiPath in the 4th quarter valued at $15,543,000. O Shaughnessy Asset Management LLC bought a new stake in shares of UiPath in the third quarter valued at about $203,000. Invesco Ltd. grew its stake in shares of UiPath by 2.8% in the third quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock valued at $6,830,000 after acquiring an additional 10,863 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in UiPath by 13.9% in the 4th quarter. California Public Employees Retirement System now owns 641,825 shares of the healthcare company’s stock worth $15,943,000 after purchasing an additional 78,459 shares in the last quarter. 62.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PATH. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $29.00 target price on shares of UiPath in a report on Monday, April 1st. KeyCorp assumed coverage on shares of UiPath in a report on Monday, April 8th. They set an “overweight” rating and a $27.00 price objective for the company. Evercore ISI boosted their target price on UiPath from $24.00 to $27.00 and gave the company an “in-line” rating in a research note on Thursday, March 14th. JPMorgan Chase & Co. raised UiPath from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $22.00 to $28.00 in a research report on Thursday, March 14th. Finally, Mizuho boosted their price objective on UiPath from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Thursday, March 14th. Nine research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $27.41.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.